1524P - Combination of three cytotoxic agents in small cell lung cancer

Date 30 September 2012
Event ESMO Congress 2012
Session Poster presentation II
Topics Anti-Cancer Agents & Biologic Therapy
Small-Cell Lung Cancer
Presenter Georgios Stathopoulos
Authors G.T. Stathopoulos1, D. Traphalis1, J. Dimitroulis2, C. Kosmas3, J. Stathopoulos1, D. Tsavdaridis4
  • 1A' Oncology Clinic Errikos Dunant, Dr. Georgios Stathopoulos, 115 28 - Athens/GR
  • 26th Pneumonic Clinic, Hospital for thoracic disease, Athens/GR
  • 3Oncology Clinic, Anticancer Hospital Piraeus, Piraeus/GR
  • 4Oncology Clinic, Anticancer Hospital, Thessaloniki/GR



Small-cell lung cancer treatment has been tested by using combinations of several cytotoxic agents. For quite a number of years, the established treatment has been cisplatin and etoposide as the most effective chemotherapy regimen. Paclitaxel has also been used in combination with cisplatin and etoposide; the latter three - drug treatment has been effective but unacceptable due to toxicity.

Patients and methods

In the present trial we tested the aforementioned three-drug combination and avoided the toxicity in the majority of the patients by administering all 3 drugs on day 1 instead of on the established three days of treatment. Fifty patients were recruited from 5 oncology clinics. All patients had histologically- or cytologically- confirmed small-cell-lung cancer with limited and extensive disease in 40% and 60% of the patients respectively. Treatment was as follows: cisplatin 75mg/m2, etoposide 120mg/m2 with no dosage higher than 200mg/m2 and paclitaxel 135mg/m2. The agents were administered on day 1 and repeated every three weeks for 6 cycles in total.


The median survival was 14 months (95% CI 10.6-17.4) Forty-five patients (90%) achieved a response: 20(40%) patients a complete response and 25 (50%) a partial response. Adverse reactions was grade 3 and 4 neutropenia in 12% and 2% of the patients, respectively. Other side effects involved very low toxicity.


The one-day three-agent (cisplatin, etoposide, paclitaxel) treatment of small-cell lung cancer is beneficial with respect to response rate and survival, and has low and well-tolerated toxicity.


All authors have declared no conflicts of interest.